Titan Medical Inc.

Greetings and welcome to Titan Medical's second quarter 2021 earnings results call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host today, Kristen Galfetti with Investor Relations. Thank you. You may begin.

Thank you, Operator. Good morning, everyone, and thank you for joining us for Titan Medical's second quarter 2021 earnings conference call. During our call, we will review Titan's second quarter 2021 financial results and key business highlights, which were summarized in our earnings press release issued earlier this morning. A copy of the release can be found in the investor relations section of our website at www.titanmedicalinc.com. As a reminder, certain statements made during this conference call constitute forward-looking statements that reflect management's current expectations of the company's future growth, results of operations, performance and business prospects, and opportunities. Wherever possible, words such as may, would, could, will, anticipate, believe, plan, expect, intend, estimate, potential for, as planned, and similar expressions have been used to identify these forward-looking statements. These statements, including statements with respect to projected development plans, milestones, timelines, budgets, development status, anticipatory regulatory pathway, including the anticipated filing and receipt of marketing authorization, anticipated biocompatibility testing results, and completion of GLP studies, anticipated license payments, anticipated loan repayment, the maintaining of worldwide rights to commercialize the technology's intellectual property license to Medtronic, the status of our patent portfolio, the goals that Eno's system is being designed to address, the features that the Eno's system is being designed to include, the medical outcomes that we expect the Eno's system will improve, the advantages that we expect users of the Eno's system will receive, the anticipated market demand and patient motivation for embracing the Eno's system, and the belief that the market is under-penetrated, the potential future market expansion from the Eno's system, Anticipated product launch and plans to participate in certain investor conferences reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties, and assumptions. Many factors could cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the Risk Factors section of the company's Annual Information Form and Form 40F for the fiscal year ended December 31, 2020, which may be viewed at www.cedar.com and at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements provide incorrect, Actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements made during this conference call. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements made during this conference call are based upon what management currently believes to be reasonable assumptions, the company cannot assure current or prospective investors that actual results, performance, or achievements will be consistent with these forward-looking statements. With that, I will turn the call over to David McNally, President and Chief Executive Officer of Titan Medical.

David.